title: The effect of venlafaxine on behaviour, body weight and striatal monoamine levels on sleep-deprived female rats.
abstract: Partial sleep deprivation is clinically associated with fatigue, depressive symptoms and reduced memory. Previously, it has been demonstrated that venlafaxine, an atypical antidepressant, increases the levels of noradrenaline and serotonin in rat hippocampus. The aim of this study was to evaluate the effects of venlafaxine on depression, anxiety, locomotor activity and memory in a model of REM sleep (REMs) deprivation in rats. We have also studied the influence of venlafaxine on monoamine levels in the striatum. Six groups of animals (N=20 each) were treated with saline or venlafaxine (1 or 10 mg/kg) during 10 days, submitted or not to REMs deprivation and studied with the forced swimming test of Porsolt (STP), plus-maze, passive avoidance and open-field tests right after sleep deprivation. Animals were also studied for passive avoidance 24 h later (rebound period). Brain samples for monoamine measurements were collected either immediately after REMs deprivation or after 24 h. Both REMs deprivation and venlafaxine showed an antidepressant effect. An anxiolytic effect was also observed after REMs deprivation. Previous treatment with venlafaxine blocked the antidepressant and anxiolytic effects of REMs deprivation. REMs deprivation alone and treatment with venlafaxine 10 mg/kg increased locomotor activity, and this effect was inhibited by venlafaxine in REMs deprived rats. Both venlafaxine treatment and REMs deprivation induced weight loss. Venlafaxine treatment, but not REMs deprivation, induced an increase in striatal dopamine (DA) levels. The combination of REMs deprivation and venlafaxine treatment was associated with an increase in serotonin turnover 24 h after rebound sleep. In this study, venlafaxine treatment hindered most behavioral effects of REMs deprivation and was associated with an interference on dopamine and serotonin systems in the striatum.
authors.affiliation: Department of Clinical Medicine, Federal University of Ceará, Brazil, Prof Costa Mendes 1608 4o. Andar, CEP 60430140 Fortaleza, Ceará, Brazil.
authors.forename: Ricardo A
authors.initials: RA
authors.lastname: de Oliveira
authors.forename: Geanne M A
authors.initials: GM
authors.lastname: Cunha
authors.forename: Karla Daisy M
authors.initials: KD
authors.lastname: Borges
authors.forename: Gabriela S
authors.initials: GS
authors.lastname: de Bruin
authors.forename: Emídio A
authors.initials: EA
authors.lastname: dos Santos-Filho
authors.forename: Glauce S B
authors.initials: GS
authors.lastname: Viana
authors.forename: Veralice M S
authors.initials: VM
authors.lastname: de Bruin
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects* / Q000502:physiology; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D003511:Cyclohexanols / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D007103:Immobilization / Q000502:physiology; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology; D008568:Memory / Q000187:drug effects / Q000502:physiology; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D012892:Sleep Deprivation / Q000188:drug therapy / Q000378:metabolism*; D000069470:Venlafaxine Hydrochloride
chemical_list: D003511:Cyclohexanols; D000069470:Venlafaxine Hydrochloride